CD274 and neoplasm: Similar to our results, a previous study has demonstrated that after treatment with nivolumab for six months, patients with PD‐L1 negative circulating tumor cells (CTCs) all obtained a clinical benefit, while patients with PD‐L1 positive CTCs all had PD.30